Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Roche keeps Venclexta train rolling with new leukaemia filing

Roche keeps Venclexta train rolling with new leukaemia filing

Roche and partner AbbVie have filed their fast-growing blood cancer drug Venclexta in the US as a first-line treatment for acute myelogenous leukaemia (AML), a key new indication for ... this very difficult-to-treat blood cancer as soon as possible.”.

Latest news

More from news
Approximately 9 fully matching, plus 209 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Taking a strategic approach Taking a strategic approach

    proposed submitting further evidence and an amended patient access scheme for its prostate cancer drug. ... In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers. ... 85. Agios Pharmaceuticals / Celgene. R&D collaboration and profit share. AG-881 IDH (isocitrate dehydrogenase) mutant

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... which comes off patent

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100, ... NICE, however, has been asked to consider its use to treat atypical

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • Cancer communications; it's in our blood

    Cancer communications; it's in our blood. We have years of experience working in cancer communications, partnering with some of the biggest brands, institutions and societies. ... From solid tumours to blood cancer, from patients to professionals; within

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics